ILP2 antibody Polyclonal Antibodies Primary antibodies
- Known as:
- ILP2 (anti-) Polyclonal Antibodies Primary antibodies
- Catalog number:
- orb100022
- Product Quantity:
- 100
- Category:
- -
- Supplier:
- Biorb
- Gene target:
- ILP2 antibody Polyclonal Antibodies Primary antibodies
Related genes to: ILP2 antibody Polyclonal Antibodies Primary antibodies
- Gene:
- BIRC8 NIH gene
- Name:
- baculoviral IAP repeat containing 8
- Previous symbol:
- -
- Synonyms:
- ILP-2, hILP2, RNF136
- Chromosome:
- 19q13.42
- Locus Type:
- gene with protein product
- Date approved:
- 2001-08-23
- Date modifiied:
- 2019-04-04
Related products to: ILP2 antibody Polyclonal Antibodies Primary antibodies
Related articles to: ILP2 antibody Polyclonal Antibodies Primary antibodies
- Intestinal neuroendocrine tumours (I-NETs) represent a non-negligible entity among intestinal neoplasms, with metastatic spreading usually present at the time of diagnosis. In this context, effective molecular actionable targets are still lacking. Through transcriptome analysis, we aim at refining the molecular taxonomy of I-NETs, also providing insights towards the identification of new therapeutic vulnerabilities. - Source: PubMed
Publication date: 2023/07/07
Mattiolo PaolaGkountakos AnastasiosCentonze GiovanniBevere MichelePiccoli PaolaAmmendola SerenaPedrazzani CorradoLandoni LucaCingarlini SaraMilella MicheleMilione MassimoLuchini ClaudioScarpa AldoSimbolo Michele - Due to their therapeutic potential, mesenchymal stem cells are the subject of intensive research on the use of their potential in the treatment of, among others, neurodegenerative diseases or immunological diseases. They are among the newest in the field of medicine. The presented study aimed to evaluate the expression of eight genes from the IAP family and the gene regulating IAP--in stem cells derived from human milk, using the qPCR method. The relationships between the expression of genes under study and clinical data, such as maternal age, maternal BMI, week of pregnancy in which the delivery took place, bodyweight of the newborn, the number of pregnancies and deliveries, and the time elapsed since delivery, were also analyzed. The research was carried out on samples of human milk collected from 42 patients hospitalized in The Clinic of Obstetrics and Perinatology of the Independent Public Clinical Hospital No. 4, in Lublin. The conducted research confirmed the expression of the following genes in the tested material: and . Moreover, several dependencies of the expression of individual genes on the maternal BMI ( and ), the time since childbirth ( and ), the number of pregnancies and deliveries ( and ), the manner of delivery ( and ), preterm labor ( and ) were demonstrated. Additionally, we found positive relationships between gene expression of BIRC7, BIRC8 and XAF1 and the main factors of pluripotency: and . This work is the first to investigate the expression of genes from the IAPs family in mother's milk stem cells. - Source: PubMed
Publication date: 2023/01/27
Gil-Kulik PaulinaLeśniewski MichałBieńko KarolinaWójcik MonikaWięckowska MartaPrzywara DominikaPetniak AlicjaKondracka AdriannaŚwistowska MałgorzataSzymanowski RafałWilińska AgnieszkaWiliński MateuszPłachno Bartosz JKostuch MarzenaRahnama-Hezavach MansurSzuta MariuszKwaśniewska AnnaBogucka-Kocka AnnaKocki Janusz - Inhibitor of apoptosis protein-related-like protein-2 (ILP-2), also known as BIRC-8, is a member of the inhibitor of apoptosis protein (IAPs) family, which mainly encodes the negative regulator of apoptosis. It is selectively overexpressed in a variety of human tumors and can help tumor cells evade apoptosis, promote tumor cell growth, increase tumor cell aggressiveness, and appears to be involved in tumor cell resistance to chemotherapeutic drugs. Several studies have shown that downregulation of ILP-2 expression increases apoptosis, inhibits metastasis, reduces cell growth potential, and sensitizes tumor cells to chemotherapeutic drugs. In addition, ILP-2 inhibits apoptosis in a unique manner; it does not directly inhibit the activity of caspases but induces apoptosis by cooperating with other apoptosis-related proteins. Here, we review the current understanding of the various roles of ILP-2 in the apoptotic cascade and explore the use of interfering ILP-2, and the combination of related anti-tumor agents, as a novel strategy for cancer therapy. - Source: PubMed
Publication date: 2022/06/23
Zhang ZhiliangXiang SiqiCui RuxiaPeng HangMridul RoyXiang Mingjun - Fisetin, a flavonol profusely found in vegetables and fruits, exhibited a myriad of properties in preclinical studies to impede cancer growth. - Source: PubMed
Publication date: 2022/02/01
Afroze NaziaPramodh SreepoornaShafarin JasminBajbouj KhuloudHamad MawiehSundaram Madhumitha KedhariHaque ShafiulHussain Arif - Non-responsive subpopulation of tumor cells, and acquired resistance in initially responsive cells are major challenges for cancer therapy with molecularly-targeted drugs. While point mutations are considered the major contributing factor to acquired resistance, in this study we explored the role of heterogeneity and plasticity of selected human breast cancer cell lines (MDA-MB-231, MDA-MB-468, and AU565) in their initial and adjusted response, respectively, to ruxolitinib, everolimus, and erlotinib. After determination of lethal concentration for 50% cell death (LC50), cells were exposed to selected drugs using three different approaches: single exposure to 4 × LC50 and collection of surviving cells, multiple exposures to 1.5 × LC50 and monitoring the surviving population, and exposure to gradually increasing concentrations of selected drugs (range of concentrations equivalent to 10% of LC50 to 1.5 × LC50). Surviving cells were studied for adjustments in expression level of selected proteins using quantitative PCR and Western Blot. Our data indicated overexpression of a variety of proteins in resistant populations, which included cell membrane receptors EGFR and HER2, anti-apoptotic proteins Bcl-2 and BIRC8, and other proteins involved in cell signaling (e.g., Akt1, MAPK7, and RPS6KA5). Silencing the identified alternative proteins via siRNA resulted in significant drop in the LC50 of the selected molecularly-targeted drugs cells resistant to ruxolitinib (via targeting Akt), everolimus (via targeting EGFR, MAPK7, RPS6KA5, and HER2), and erlotinib (via silencing Bcl2 and BIRC8). Our data indicates that targeting well-selected alternative proteins could potentially sensitize the resistant cells to the effect of the molecularly-targeted treatment. - Source: PubMed
Publication date: 2019/10/15
Bousoik EmiraNabiee RaminaAmirrad FaridehNichols AshleyWitt RebeccaMahdipoor ParvinMontazeri Aliabadi Hamidreza